Shandong Jincheng Pharmaceutical Group Co., Ltd. Announcement on Provision for Asset Impairment
The company and all members of the board guarantee that the information disclosed is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
I. Overview of the Provision for Asset Impairment
To more accurately reflect the company's financial position as of March 31, 2026, and the operating results for the first quarter of 2026, the company conducted impairment tests on various assets within the scope of the consolidated financial statements according to the "Enterprise Accounting Standards" and relevant accounting policies. The company has made provisions for impairment on relevant assets showing signs of impairment as of March 31, 2026.
II. Scope, Total Amount, and Reporting Period of the Provision
The company has made a total provision for asset impairment of 5.8143 million yuan for assets within the scope of the consolidated financial statements that showed signs of impairment in the first quarter of 2026, detailed in the table below: